Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

European Research Council grant · Running

geNEOMORPH Chemical Rewiring of Oncogenic Transcription

Coordinator
Aithyra GmbH Research Institute for Biomedical Artificial Intelligence of the Austrian Academy of Sciences, Austria
Runs
1 August 2025 to 31 July 2030
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101170771

What the project is doing

In the project's own words, from its summary on CORDIS.

Many cancers are driven by mutations affecting transcription regulation. Through cancer genome sequencing studies, we understand that these aberrations are pervasive through many layers of gene control. Yet, with few exceptions, this knowledge has not precipitated in effective treatments since pharmacologic inhibition of transcription is often infeasible or functionally inconsequential. To address this limitation, I want to innovate chemical strategies that move beyond loss of function (LOF) approaches.

Gene control is organized at the level of proximity. Hence, I hypothesize that transcriptional regulators can be chemically rewired by neomorphic small molecules that recruit functionally opposing gene-regulatory effectors, thereby prompting an acute, deep, and sustained disruption of oncogenic transcriptional circuits. The identification, characterization, and translation of such Neomorphic Transcriptional Compounds (NeoTraCs) will be the subject of the GE|NEomorph proposal.

We will focus on NeoTraCs to rewire the repressive PRC2 complex, the p400 chromatin regulator complex, and the non-canonical BAF complex. While these targets have established roles in various cancers, inhibitors are not available or have limited functional impact. To identify NeoTraCs that address these limitations, we will implement a diverse discovery approach that incorporates hypothesis-driven design with phenotypic strategies geared to co-opt undrugged transcriptional effectors via bivalent NeoTraCs, and unligandable effectors via molecular glue-like NeoTraCs.

Identified hits will be characterized via multi-omics approaches. Through careful mechanistic investigation, we will deduce general mechanistic principles, understand their impact on oncogenic transcription and investigate associated translational opportunities. GE|NEomorph will significantly advance our ability to understand and disrupt transcriptional dysregulation in cancer and pave the way for novel innovative therapies.

Topics

Who is involved

OrganisationCityCountryRole
Aithyra GmbH Research Institute for Biomedical Artificial Intelligence of the Austrian Academy of SciencesViennaAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI